GSK3B and type 2 diabetes mellitus: T2D reduces GSK‐3β phosphorylation, which activates GSK‐3β, leading to inhibition of glycogen synthase, impaired glycogen synthesis and eventually insulin resistance.32 MH treatment increased the phosphorylation of GSK‐3β which was previously reduced by T2D.